Business Wire

BATON-SYSTEMS

13.12.2021 10:31:08 CET | Business Wire | Press release

Share
Baton Systems’ Technology Powers the World’s First Interbank Riskless Settlement Outside Of CLS

The world’s first interbank Payment vs Payment (PvP) settlement outside of CLS has been completed using Baton SystemsCore-FX solution, built on Baton’s proprietary distributed ledger technology (DLT) and governed by the Baton Rulebook.

Standing at the threshold of a new era in FX settlements, two of the world’s largest financial institutions are now using the platform to collaboratively settle FX trades bilaterally on demand using real currencies in real accounts, in less than three minutes, on a PvP basis with legal settlement finality. The solution enables the firms to net in an efficient manner, choose what time to settle and in which currencies, all on a PvP basis - reducing settlement risks and FX processing costs.

This historic move marks the inception of a profound change in FX settlements. All market participants now have the opportunity to radically reduce their settlement exposure and associated risks outside of the CLS framework. All currencies, including emerging market currencies, which are ineligible for PvP settlement in CLS, can now be securely settled using distributed ledger technology that provides extensive flexibility and complete transparency.

Aligned with an enhanced regulatory focus on expanding and extending riskless settlement more broadly across the market, Baton’s innovative PvP solution empowers market participants to take direct control of their settlement cycles, settle multiple times a day, and streamline workflows, resulting in significant improvements to their liquidity, funding, risk and credit management.

The availability of this transformative technology provides a long overdue alternative to a market previously hamstrung by restrictive batch-based processes and limited PvP access at both a participant and currency level.

Arjun Jayaram, CEO and Founder of Baton Systems, commented: “This development is hugely significant for the entire FX market, as it offers firms the opportunity to really address settlement risk - arguably the most critical control issue impacting post-trade today. Today’s announcement demonstrates the tremendous potential this technology presents to FX market participants globally to improve their risk management, intraday liquidity controls and funding profiles. Using proven technology that is readily available today, banks can now take control and completely revolutionise their entire post-trade process from trade-capture through to settlement.”

As part of the implementation both banks have agreed to the Baton Rulebook, a framework designed to provide legal certainty around settlement finality. Baton is engaging with other leading FX trading businesses, as well as regulators globally, to expand market access to fast and riskless PvP settlement protection to a wider universe of participants.

ENDS

About Baton Systems

Baton Systems is revolutionising the entire front-to-back post-trade process, introducing interoperable and connected digital market infrastructures from trade matching through to settlement. Empowering financial institutions to take control with automated, rules-based workflows, access to real-time information, and on-demand settlement, Baton is redefining what post-trade processing should look like: fully connected, friction-free, flexible and transparent.

Founded in 2016 by Silicon Valley technologists and capital market specialists, Baton’s solutions are now being used by several of the world’s largest financial institutions to facilitate the movement of billions of dollars of cash and securities on a daily basis.

Find out more at www.batonsystems.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release

Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release

CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla

BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release

Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho

Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release

NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi

KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release

Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye